☆ 4.8 Article

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

NEW ENGLAND JOURNAL OF MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Luis G. Paz-Ares et al.

Summary: Nivolumab plus ipilimumab continues to demonstrate durable long-term efficacy in patients with advanced NSCLC, with a significant improvement in overall survival compared to chemotherapy. Immune-mediated adverse events occur early but can be managed with guideline-based treatment. Discontinuation of nivolumab plus ipilimumab due to adverse events does not impact the long-term benefits seen in all randomized patients.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Correction Oncology

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate O17 and O57: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (vol 39, pg 723, 2021)

Borghaei

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares et al.

Summary: The combination of first-line nivolumab plus ipilimumab with a limited course of chemotherapy showed a significant improvement in overall survival for patients with advanced non-small-cell lung cancer, supporting it as a new treatment option for this patient population.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival

M. J. M. Magbanua et al.

Summary: The study investigated the utility of serial ctDNA testing in predicting pCR and risk of metastatic recurrence during neoadjuvant chemotherapy for high-risk early breast cancer patients. The results showed that lack of ctDNA clearance was a significant predictor of poor response and metastatic recurrence, while clearance was associated with improved survival even in patients who did not achieve pCR. Personalized monitoring of ctDNA during NAC may aid in real-time assessment of treatment response and help fine-tune pCR as a surrogate endpoint of survival.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

M. Provencio et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Article Oncology

OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

A. Romero et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Alexander M. Menzies et al.

Summary: A pooled analysis of neoadjuvant immunotherapy trials in melanoma revealed that the degree of pathological response is correlated with patient survival, serving as a potential surrogate marker for long-term outcomes. Patients with pathological complete response (pCR) after immunotherapy showed significantly improved recurrence-free survival (RFS) and overall survival (OS) compared to those without pCR. Pathological response, particularly pCR, could be an early surrogate endpoint for clinical trials and a new benchmark for development and approval in melanoma.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone et al.

Summary: The NEOSTAR trial showed that neoadjuvant treatment with nivolumab + ipilimumab combination therapy can improve pathologic response rates in operable NSCLC patients and has better clinical efficacy compared to nivolumab alone.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip et al.

Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.

LANCET (2021)

添加到收藏夹

Article Oncology

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Hossein Borghaei et al.

Summary: Immunotherapy with nivolumab has shown improved overall survival and safety compared to docetaxel in patients with advanced NSCLC in two phase III trials. Pooled 5-year data demonstrated a significant survival benefit with nivolumab and no new safety concerns.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

William D. Travis et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Review Multidisciplinary Sciences

Neoadjuvant checkpoint blockade for cancer immunotherapy

Suzanne L. Topalian et al.

SCIENCE (2020)

添加到收藏夹

Meeting Abstract Oncology

Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): Systematic literature review and meta-analysis

N. A. Waser et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches

Dipesh Uprety et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Mariano Provencio et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Yi-Long Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

99PComparison of platforms for determining tumor mutational burden (TMB) from blood samples in patients with non-small cell lung cancer (NSCLC)

J Baden et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis

L Paz-Ares et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

Valsamo Anagnostou et al.

CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

T. R. Cottrell et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

P. M. Forde et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Oncology

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Spencer C. Wei et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Article Oncology

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Naiyer A. Rizvi et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Corey J. Langer et al.

LANCET ONCOLOGY (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Pneumonectomy for lung cancer: Contemporary national early morbidity and mortality outcomes

Pascal A. Thomas et al.

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2015)

添加到收藏夹

Review Biochemistry & Molecular Biology

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

L. Bracci et al.

CELL DEATH AND DIFFERENTIATION (2014)

添加到收藏夹

Review Medicine, General & Internal

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

Sarah Burdett et al.

LANCET (2014)

添加到收藏夹

Article Medicine, General & Internal

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Patricia Cortazar et al.

LANCET (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer

Matthew D. Taylor et al.

ANNALS OF THORACIC SURGERY (2012)

添加到收藏夹

Article Oncology

Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non-Small-Cell Lung Cancer Combined Analysis of Two IFCT Randomized Trials

Guillaume Mouillet et al.

JOURNAL OF THORACIC ONCOLOGY (2012)

添加到收藏夹

Article Oncology

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy

Apar Pataer et al.

JOURNAL OF THORACIC ONCOLOGY (2012)

添加到收藏夹

Article Oncology

Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group

Jean-Pierre Pignon et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.